ArticlemBio2017
Vaccination with Recombinant
Article in mBio, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 91 citations in OpenAlex.
- Article
- Acetylation and accessibility ofCell surface (Amsterdam, Netherlands) · 2026Article
- A review of the current anti-New microbes and new infections · 2026Review
- The structural language of fungal cell wall sugars in WHO priority fungi: the determinant of pathogenicity and the gateway to new therapies.Frontiers in immunology · 2026Review
- Review
- Vaccine-Mediated Protection of Mice Against African and Asian Clinical Strains ofJournal of fungi (Basel, Switzerland) · 2025Article
- Pathogenicity and virulence of Cryptococcus neoformans from an environmental perspective.Virulence · 2025Review
- Dendritic Cell-Based Therapeutic Immunization Induces Th1/Th17 Responses and Reduces Fungal Burden in Experimental Sporotrichosis.Microorganisms · 2025Article
- Peripheral blood CD4The Journal of infection · 2025Article
- Evolutionary uniqueeLife · 2025Article
- Fungal β-Glucans: Biological Properties, Immunomodulatory Effects, Diagnostic and Therapeutic Applications.Infectious diseases & clinical microbiology · 2025Review
- Identification of a protective antigen reveals the trade-off between iron acquisition and antigen exposure in a global fungal pathogen.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Will the Real Immunogens Please Stand Up: Exploiting the Immunogenic Potential of Cryptococcal Cell Antigens in Fungal Vaccine Development.Journal of fungi (Basel, Switzerland) · 2024Review
- Article
- Article
- Article
- Inbred Mouse Models inJournal of fungi (Basel, Switzerland) · 2024Review
- Fungal vaccines and adjuvants: a tool to reveal the interaction between host and fungi.Archives of microbiology · 2024Review
- Bacillus subtilis: current and future modification strategies as a protein secreting factory.World journal of microbiology & biotechnology · 2024Review
- Adjuvant ArtinM favored the host immunity againstImmunotherapy · 2024Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
Abstract
Development of a vaccine to protect against cryptococcosis is a priority given the enormous global burden of disease in at-risk individuals. Using glucan particles (GPs) as a delivery system, we previously demonstrated that mice vaccinated with crude
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.